Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

NCT06687603 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this clinical trial is to develop a method to detect Barrett's esophagus in individuals with a new office based diagnostic test. Barrett's esophagus is a condition in which the flat pink lining of the swallowing tube that connects the mouth to the stomach (the esophagus) becomes damaged by acid reflux. The main question it aims to answer is: Can this approach demonstrate efficacy for screening of Barrett's esophagus? Participants will: * Participate in a questionnaire. * Undergo a capsule balloon test, called EsoCheck. * Have their EsoCheck sample sent to the laboratory for an EsoGuard test, which is used to detect Barrett's esophagus. * Participants will undergo upper endoscopy as part of standard of care.

Interventions

  • DEVICE EsoCheck
  • DIAGNOSTIC_TEST EsoGuard

Study Locations (5)

Ohio

  • University Hospitals Cleveland Medical Center — Cleveland
  • Cleveland Clinic Taussig Cancer Center — Cleveland

Colorado

  • University of Colorado — Aurora

Maryland

  • Johns Hopkins Hospital — Baltimore

North Carolina

  • University of North Carolina at Chapel Hill — Chapel Hill

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2025-03-10
Est. Completion 2029-09-27
Phase NA

Sponsor

Case Comprehensive Cancer Center

276 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06687603

The ClinicalTrials.gov registry entry for NCT06687603 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 276 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 3 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions — of which EsoCheck is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06687603 reports 5 study locations spanning 4 distinct geographic areas — top geographies include Ohio, Colorado, Maryland. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06687603 about?

NCT06687603 is a clinical study titled "Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms". The goal of this clinical trial is to develop a method to detect Barrett's esophagus in individuals with a new office based diagnostic test. Barrett's esophagus is a condition in which the flat pink lining of the swallowing tube that connects the mouth to the stomach (the esophagus) becomes damaged ...

What is the current status of trial NCT06687603?

This trial is currently recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2025-03-10. Estimated completion is 2029-09-27.

What conditions does trial NCT06687603 study?

This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett Esophagus, Gastroesophageal Reflux. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06687603?

The interventions under investigation include: EsoCheck (DEVICE), EsoGuard (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06687603?

This trial is sponsored by Case Comprehensive Cancer Center, which has 276 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06687603 being conducted?

This trial has 5 study locations across Colorado, Maryland, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial